Record Number of Scientific Papers Published About Cannabis in 2022

Record Number of Scientific Papers
Published About Cannabis in 2022

27.12.2022

Researchers worldwide published a record 4,300+ scientific papers on the subject of cannabis, according to the results of a keyword search of the National Library of Medicine/PubMed.gov website.

This exceeds the total number of papers published during all of last year, when scientists published over 4,200 papers. At the time, that total was the highest number of cannabis-specific papers ever published in a single year.

Since 2010, scientists have published over 30,000 peer-reviewed papers specific to cannabis, with the annual number of total papers increasing every year. By comparison, researchers published fewer than 3,000 total papers about marijuana in the years between 1990 and 1999 and fewer than 2,000 total studies during the 1980s.

“Despite claims by some that marijuana has yet to be subject to adequate scientific scrutiny, scientists’ interest in studying cannabis has increased exponentially in recent years, as has our understanding of the plant, its active constituents, their mechanisms of action, and their effects on both the user and upon society,” NORML’s Deputy Director Paul Armentano said. “It is time for politicians and others to stop assessing cannabis through the lens of ‘what we don’t know’ and instead start engaging in evidence-based discussions about marijuana and marijuana reform policies that are indicative of all that we do know.”

Much of this uptick in scientific interest surrounding cannabis is a result of researchers’ newfound focus on marijuana’s therapeutic activities. A 2018 paper assessing trends in cannabis-related publications concluded that the total number of peer-reviewed publications dedicated to medical cannabis has increased nine-fold since the year 2000.

In all, PubMed.gov now cites over 42,500 scientific papers on marijuana. Available to the public online since 1996, PubMed is a free resource supporting the search and retrieval of biomedical and life sciences literature.

Summaries of over 450 studies assessing the safety and therapeutic efficacy of cannabis and cannabinoids in different patient populations is available online from NORML.


SynBiotic SE attracts Canopy Growth founder Bruce Linton as Chairman of newly created Advisory Board

 SynBiotic SE attracts Canopy Growth founder Bruce Linton as Chairman of newly created Advisory Board

24.11.2022

Munich, 24th November 2022:

SynBiotic SE, (SBX.DE) one of Germany’s leading cannabinoid companies, accelerates implementation of the operational platform to achieve market leadership in the upcoming national legalization of recreational cannabis by securing Bruce Linton to its team.

Mr. Linton is one of the most experienced and most successful cannabis entrepreneurs and investors globally and has been the driving force behind the creation of multiple global multi-billion dollar cannabis enterprises, several of them listed on NYSE, Nasdaq, TSX, TSX:V, CSE and ASX.

Most notably, Mr. Linton is the founder and former Chairman and CEO of the global cannabis company Canopy Growth Corporation, which, at the time of his departure, had a market valuation of approximately CAD 20 billion and more than 25% market share in the Canadian recreational market while also being a global top tier supplier. Canopy was the first North American supplier to the German medical cannabis market. Combining unparalleled expertise in the areas of both medical and recreational cannabis, Mr Linton is a powerful asset given SynBiotic’s expansion plans, which cover both segments.

Mr. Linton has been appointed as Chairman of SynBiotic’s newly created Advisory Board and has invested capital in the company’s most recent financing round. His investment plus options to buy further shares from existing shareholders will bring him to an ownership of approx. 5% in SynBiotic.

He will draw no fixed cash salary and will be remunerated based on share price performance and other operational milestones, giving him full alignment with shareholders.

Mr. Linton stated “I see enormous potential in the European market, particularly in Germany because of the recently announced legalization in Europe’s largest economy. I regard SynBiotic as best positioned to take full advantage of the legalization and become Europe’s dominant cannabis company. I am very much looking forward to being part of this success story and to working with the amazing team around founder Lars Müller.“

Lars Müller, CEO of SynBiotic SE, states: “The fact that we are working with Bruce Linton is a true accolade. With the forthcoming legalization of recreational cannabis in Germany, SynBiotic SE will benefit massively from the know-how of one of the global industry pioneers. His faith in SynBiotic SE is a great honor for me and shows us that we are on the right track with our vision.“

About SynBiotic SE

SynBiotic SE is the largest listed group of companies in Europe in the hemp and cannabis sector and pursues a buy-&-build investment strategy focused across the European Union. The group of companies covers the entire supply chain from cultivation through production to retail – from field to shelf. A core business of the company is the research & development, production and marketing of cannabinoid and terpene-based solutions to address major societal problems such as pain, sleep deprivation and anxiety. In addition to the food supplement and cosmetics market, SynBiotic SE is also active in the medical sector, and will shortly also enter the recreational cannabis sector.


24.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


SynBiotic SE schließt Kapitalerhöhung ab

SynBiotic SE schließt Kapitalerhöhung ab

27.09.2022

München, 27. September 2022 – Die SynBiotic SE hat die am 2. September 2022 beschlossene Barkapitalerhöhung abgeschlossen. Es konnten 142.261 Neue Aktien zum Bezugspreis in Höhe von EUR 12,00 je Neuer Aktie platziert werden. Aus dieser Kapitalerhöhung ergibt sich somit ein Bruttoemissionserlös in Höhe von EUR 1.707.132,00.

Die Durchführung dieser Kapitalerhöhung soll voraussichtlich Anfang Oktober 2022 in das Handelsregister der Gesellschaft eingetragen werden. Die Einbeziehung in den Handel des Primärmarktes der Börse Düsseldorf und die Lieferung der Neuen Aktien wird voraussichtlich Mitte Oktober 2022 erfolgen.

Der Nettoemissionserlös aus der Kapitalerhöhung soll zur Finanzierung der Geschäftstätigkeit und Erweiterung durch mögliche Beteiligungen der SynBiotic SE eingesetzt werden.

Weitere Informationen stehen unter https://www.synbiotic.com bereit.


Ready to Go

Ready to Go

01.09.2022

Pünktlich nach der Sommerpause startet das neu formierte SynBiotic Sales Key Account Team unter der Führung von Markus Zitzmann-Schreiner mit zunächst 10 Kollegen bei Ärzten und im Apotheken-Markt.

Bis zum Jahresbeginn 2023 wird das Team dann auf 15 Kollegen im Außendienst hochgefahren. Nach intensiven Auswahlprozessen konnte eine professionelle Selektion aus Medizinal-Cannabis erfahrenen – und jungen, motivierten Kollegen gewonnen werden, die jetzt mit der Marke Hempamed Rx starten.

Ab September wird Dronabinol, im Oktober werden dann Extrakte und ab Dezember erste Blüten unter der Marke Hempamed Rx besprochen. Weitere Innovationen sind in der Entwicklung und folgen in 2023.

RK – Wiesbaden, 1.09.2022